Initiated Buy X

MIST Milestone Pharmaceuticals

Rodman & Renshaw

$9

Downgrades Buy Hold X

MIST Milestone Pharmaceuticals

Jefferies

$8 $4

Upgrades Neutral Overweight X

MIST Milestone Pharmaceuticals

Piper Sandler

$8 $10

Initiated Buy X

MIST Milestone Pharmaceuticals

H.C. Wainwright

$20

Initiated Outperform X

MIST Milestone Pharmaceuticals

Oppenheimer

$32

Initiated Outperform X

MIST Milestone Pharmaceuticals

Cowen

$32

Initiated Buy X

MIST Milestone Pharmaceuticals

Jefferies

$28

Initiated Overweight X

MIST Milestone Pharmaceuticals

Piper Jaffray

$26.50

MIST  Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker that has completed Phase II clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating atrial fibrillation and angina. The company was founded in 2003 and is headquartered in Montréal, Canada.